NIH panel may increase gene-trial scrutiny…

Paul Smaglik

Nature, 2000, vol. 405, issue 6788, 724-724

Abstract: Washington . A working group set up by the National Institutes of Health has urged that its Recombinant DNA Advisory Committee play a greater role in determining whether gene therapy trials proceed.

Date: 2000
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/35015760 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:405:y:2000:i:6788:d:10.1038_35015760

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/35015760

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().